**Dear Editor,**

Severe fever with thrombocytopenia (SFTS) is an emerging infectious disease caused by a novel bunyavirus (SFTSV) that was widely identified in mainland China [1]. Ticks have been recognized as the vectors involved in SFTSV transmission to humans, and several domestic animals are considered potential reservoir host [1]. Therefore people who live in rural areas or have intense contact with insects or animals are at a high-risk of acquiring SFTSV infection. The disease has also been reported in Korea and Japan, indicating the possibility of spreading in the wider geographic range [2,3]. Although infection with SFTSV is associated with a self-limiting illness in the majority of individuals, it can cause severe clinical disease in a proportion of individuals [4–6]. Some individuals with severe disease proceed to the critical phase, which is associated with multiorgan dysregulation, haemorrhagic manifestation, neurological symptoms; whereas those with self-limiting disease proceed to the recovery phase without developing any of these complications [6]. But at the early phase of the disease, patients have only non-specific febrile illnesses, making it difficult to achieve clinical based diagnosis [4,5]. Furthermore, laboratory capacity to diagnose the causative etiological agents is often lacking in rural areas. Consequently, the determination of the etiological diversity that might be causing SFTS warrants investigation with intense efforts. In recent years, an increased number of vector-borne pathogens other than SFTSV has been detected from the clinically diagnosed SFTS patients, comprising species of spotted fever group rickettsiae (SFGR), Hantaan and Seoul viruses, *Orientia tsutsugamushi*, and *Anaplasma phagocytophilum* [7–10]. Moreover, the previous study found that only 27% of the SFTS like patients reported tick bite history [9], indicating that the patients might be either infested by other vectors or infected with other vector-borne pathogens. *Murine typhus* is a flea-borne febrile illness caused by *Rickettsia typhi*, and is hard to be diagnosed due to the non-specific clinical features [11]. In China mainland, *R. typhi* was only rarely reported to cause human infection. In a field epidemiological survey performed in Tianjin, the antibody positive rates determined by IFA for *R. typhi* ranged from 5.0% to 58.2% from 2007 to 2009, suggesting a high possibility of acquiring *R. typhi* infection in people living in rural areas in China [12]. In our sentinel hospital that recruited SFTS like patients in Xinyang city, although SFTSV and SFGR were found to be the most frequently seen tick-borne agents [9,10] the causative agents in a percentage of patients remained to be determined. On the other hand, *R. typhi* was indeed detected in the captured mice in the same region, with a positive rate of 6.45%, indicating the epidemic status of *R. typhi* in natural reservoir [13]. This has inspired us to undertake a clinically based surveillance study to explore the presence of *R. typhi* in SFTS endemic regions. The clinical symptoms and laboratory findings of patients infected with *R. typhi* were used to differentiate diagnosis with those of SFTSV infection.

This retrospective study was conducted in Xinyang city, Henan Province, where SFGR infection used to be determined from clinical diagnosed SFTS patients [9,10]. The region has a humid subtropical climate with annual precipitation of around 1100 millimetres. The natural landscape of the region is plain and mountain, and the main local agriculture activities include...
preparing land for cultivation, planting crops, pasturing cattle, and tea-picking activity, etc. From March to November, 2014–2015, patients with suspected vector-borne disease, which was defined as: fever with axillary temperature >38°C, and absence of a focal site of infection (e.g., pneumonia, urinary tract infection), and had a reported history of tick or other vector bite or animal contact, were recruited from the vector-borne disease clinic of the PLA 154 Hospital and the Shangcheng People’s Hospital. Paired blood samples were obtained from all consenting patients with the first and second blood collected at least more than two weeks apart. The molecular test of SFTSV, SFG rickettsiae, and other tick-borne agents, including Anaplasma phagocytophilum, Babesia microti, and Borrelia burgdorferi sensu lato, was performed in the acute serum samples by PCR or real-time PCR (Appendix Table A1), and those positive were excluded from the study. The patients with paired serum were tested for R. typhi specific IgG antibody by applying the indirect immunofluorescence assay (IFA) (Focus, USA). Titre of 1:64 of IgG antibody was considered as positive reaction. An acute infection of R. typhi was defined by seroconversion or a four-fold increase in titres of IgG antibodies between paired serum samples. A total of 1348 hospitalized patients who had illnesses meeting the case definition were recruited in 2014–2015, among whom 767 patients were confirmed with single SFTSV infection, 73 were determined to be with SFGR infections, or infections with other tick-borne agents. The other 508 patients who were negative for SFTSV were subject to anti-R. typhi antibody test. Seroconversion was evident for 60 (11.8%) patients. R. typhi less seen in infected patients, except that the myalgia was evidenced for SFTSV with a comparable frequency between SFTSV and R. typhi infection (62.0 ± 12.3 vs. 81.5%, P = .030). Only one patient had rash, while four patients had diarrhoea. The diarrhoea was less seen in R. typhi than in SFTSV infection (6.7% vs. 22.7%, P = .003).

The clinical course was complicated in 42 (70.0%) patients who presented a total of 19 complications, including pulmonary infection in 36 (60.0%), neurological manifestations in 11 (18.3%), and plasma leakage (designates as clinical presence of hydrothorax, hydropericardium or ascites) in 9 (15.0%) of the 60

| Characteristics | R. typhi infection (n = 60) | SFTS single infection (n = 767) | P-value |
|-----------------|-----------------------------|--------------------------------|--------|
| **Demographic characteristics** | | | |
| Age, Mean ± SD, years | 58.4±11.3 | 62.0±12.3 | 0.028* |
| Sex, female | 34 (56.7) | 450 (58.7) | 0.762 |
| Reported history of insect bite | 9 (15.0) | 91 (11.8) | 0.473 |
| Hospital duration, median (IQR) | 10 (8–12) | 7 (5–9) | <0.001* |
| Delay days from onset to admission, median (IQR) | 5 (4–7) | 5 (4–7) | 0.039* |
| **Clinical manifestations** | | | |
| **Common signs** | | | |
| Fever | 59 (98.3) | 764 (99.6) | 0.261 |
| Fever duration, days, median (IQR) | 5 (4–7) | 5 (4–7) | 0.039* |
| Maximum temperature, Mean ± SD, °C | 38.6±0.6 | 38.7±1.0 | 0.731 |
| Chills | 4 (6.7) | 68 (8.6) | 0.810 |
| Malaise | 56 (93.3) | 741 (96.6) | 0.267 |
| Lymphadenecasis | 32 (53.3) | 338 (44.1) | 0.165 |
| Myalgia | 42 (70.0) | 625 (81.5) | 0.030* |
| Dizziness | 10 (16.7) | 131 (17.1) | 0.935 |
| Headache | 5 (8.3) | 61 (8.0) | 0.917 |
| Rash | 1 (1.7) | 4 (0.5) | 0.314 |
| Arthralgia | 1 (1.7) | 10 (1.3) | 0.566 |
| **Respiratory syndrome** | 30 (50.0) | 378 (49.3) | 0.915 |
| Cough | 30 (50.0) | 373 (48.6) | 0.838 |
| Productive cough | 24 (40.0) | 279 (36.4) | 0.575 |
| **Gastrointestinal illness** | 54 (90.0) | 659 (85.9) | 0.377 |
| Anorexia | 27 (45.0) | 360 (46.9) | 0.772 |
| Nausea | 41 (68.3) | 496 (64.7) | 0.567 |
| Vomit | 18 (30.0) | 212 (27.0) | 0.609 |
| Abdominal pain | 3 (5.0) | 33 (4.3) | 0.740 |
| Abdominal distension | 3 (5.0) | 26 (3.4) | 0.461 |
| Diarrhoea | 4 (6.7) | 174 (22.7) | 0.003* |
| **Hemorrhage manifestations** | 14 (23.3) | 182 (23.7) | 0.945 |
| Gingival bleeding | 6 (10.0) | 51 (8.0) | 0.576 |
| Melena | 5 (8.3) | 47 (6.1) | 0.498 |
| Hemoptysis | 3 (5.0) | 29 (3.8) | 0.500 |
| Epistaxis | 1 (1.7) | 6 (0.8) | 0.411 |
| Hematuria | 4 (6.7) | 71 (9.3) | 0.644 |
| **Neurological symptom** | 11 (18.3) | 285 (37.2) | 0.003* |
| Apathy | 5 (8.3) | 159 (20.7) | 0.020* |
| Dysphoria | 3 (5.0) | 94 (12.3) | 0.099 |
| Convulsion | 5 (8.3) | 119 (15.5) | 0.133 |
| Lethargy | 2 (3.3) | 72 (9.4) | 0.156 |
| Confusion | 4 (6.7) | 147 (19.2) | 0.014* |
| Coma | 1 (1.7) | 56 (7.3) | 0.114 |
| **Plasma leakage** | 9 (15.0) | 132 (17.2) | 0.661 |
| Hydrothorax | 8 (13.3) | 123 (16.0) | 0.581 |
| Hydropericardium | 2 (3.3) | 16 (2.1) | 0.380 |
| Ascites | 2 (3.3) | 15 (2.0) | 0.353 |
| Pelvis fluidity | 0 (0.0) | 1 (0.1) | 1.000 |
| **Respiratory complications** | 37 (61.7) | 429 (55.9) | 0.388 |
| Pulmonary infection | 36 (60.0) | 368 (48.0) | 0.073 |
| Bronchitis | 6 (10.0) | 176 (23.0) | 0.020* |
| Respiratory failure | 0 | 23 (3.0) | 0.402 |
| **Renal failure** | 2 (3.3) | 20 (2.6) | 0.670 |

Notes: Continuous variables were analysed by t-test or nonparametric test; categorical variables were analysed by chi-square test or Fisher’s exact test. *P-values were 2-tailed and P < .05 was considered statistically significant.

Table1. Demographic and clinical characteristics of the patients with R. typhi infection vs. SFTSV infection, 2014–2015, China.
patients. Both neurological manifestations and presence of bronchitis were significantly lower than that of the SFTSV infection (18.3% vs. 37.2%, \( P = .003 \); 10.0% vs. 23.0%, \( P = .020 \); Table 1). Patients who presented with complications were significantly older than those without (age, 60.4 ± 10.3 vs. 53.6 ± 12.3, \( P = .031 \)), and more likely to be male.

Thrombocytopenia and leukopenia were noted from 41 (68.3%) and 49 (81.7%) cases, respectively (Appendix Table A2). Nine (15.0%) patients displayed anaemia upon admission. The most prominent biochemical finding on admission was the concurrent elevation of aspartate aminotransferase (AST) and lactate dehydrogenase above the normal level, which was observed in 42 (70.0%) patients. Elevated alanine aminotransferase and creatinine were presented in 29 (48.3%) and 32 (53.3%) of the patients, respectively. Hypoalbuminemia was only observed in 5 patients. Altogether 55 (91.7%) patients had abnormal serum electrolyte level, including hyponatremia in 44 (73.3%), hypocalcaemia in 24 (48.0%), hypochloroemia in 9 (15.5%), and hypokalaemia in 32 (53.3%). In comparison with SFTSV infected patients, only thrombocytopenia and elevated AST were significantly underrepresented in \( R. typhi \) patients (\( P = .001 \) and \( P = .031 \), respectively, Appendix Table A2), while others were comparable between two groups. The \( R. typhi \) infected patients were hospitalized for a median of 10 (IQR, 8–12) days, and fatal outcome was reported from 1 (1.7%) patient (Appendix Tables A3 and A4), significantly lower than those with SFTSV infection (17.1%, \( P < .001 \)). Among the 60 patients, 36 (60.0%) received cephalosporins treatment, 7 (11.7%) received doxycycline treatment, and 6 received levofloxacin treatment. The patients who recovered were followed and no clinical sequelae were observed on one-month observation after discharge from the hospital.

In SFTS endemic region, fever remains one of the major reasons to seek healthcare but the causes remain ill-defined. Here we provided evidence that \( R. typhi \), a flea-borne rickettsia was prevalent in this region, with clinical syndromes and laboratory abnormalities highly resembling those with SFTSV infection [10], thus pathogen spectrum of the SFTS should be further expanded. The competent vector of \( R. typhi \) existed widely in China, especially in regions with warm and humid environment. However, the human cases with \( R. typhi \) infection were rarely reported and the clinical data were lacking, contributing to a difficulty clinical diagnosis in most of the endemic region in China. Compared to the data from a systematic review [11], several common clinical features of \( R. typhi \) infection, such as headache, chills, and rash, were less frequently seen in our patients. The main reason for this inconsistency might be that our participants were all recruited from SFTS like patients. We believe that due to the lack of typical signs of \( R. typhi \) infection, misdiagnosis of \( R. typhi \) infection was likely to happen in SFTS endemic regions. The elderly patients with \( R. typhi \) infection were more prone to present severe complications, which was consistent with previous studies [11,14,15]. Due to the possibility of severe complications, the recognition of the \( R. typhi \) infection and empirical treatment with doxycycline should be stressed, especially for elderly patients in regions with abundant transmission vectors and suitable environment.

The similar clinical manifestations between \( R. typhi \) and SFTSV infections could be interpreted from the point of pathogenesis that was common between them. \( R. typhi \) proliferates and spreads via the blood stream causing injury to endothelial and vascular smooth muscle cells, composing the pathophysiologic basis for meningoencephalitis and a skin rash [16]. The haemorrhage might also be caused by increased vascular permeability that is related with the infection. Reassembling \( R. typhi \) infection, pathogenesis of SFTSV infection also involves vascular damage, which leads to an increased vascular permeability and further development of bleeding [17], the damages that underlie the similar complications observed in \( R. typhi \) infection [16]. The current finding should also be interpreted from the point of coinfection, which might likely happen. According to our previous knowledge, SFTSV coinfection with serological diagnosed spotted fever rickettsia was associated with aggravated disease [10]. Given the potential synergistic effect of SFTSV and \( R. typhi \) infection, the coinfecion should also be warned in SFTS endemic regions.

The study was subject to a major limitation. Due to the fact that event of insect bite or animal contact is most often not recalled by the patients [11], we might miss some of the patients with \( R. typhi \) infection when using this as one of the inclusion criteria, thus might underestimate the actual infection rate of \( R. typhi \). Despite the current limitation, we have confirmed \( R. typhi \) infection in SFTS like patients, described the clinical and laboratory characteristics of \( R. typhi \) infection. This information could be helpful for early differentiation between SFTSV and \( R. typhi \) infection. Further studies are needed to investigate their coinfecion in the endemic regions.

 Disclosure statement

No potential conflict of interest was reported by the authors.

 Funding

This work was supported by the National Natural Science Foundation of China [grant numbers 81825019, 81427005, 81722041 and 81621005], the China Mega-Project for Infectious Diseases [grant number 2018ZX10713002], the National Key Research and Development Program of China [grant number 2016YFX1201905], and the New Star Plan of Science and Technology of Beijing [grant number
Z17110001117089]. The funding agencies had no role in the design and conduct of the study, collection, management, analysis, interpretation of the data, preparation, review, or approval of the manuscript.

**ORCID**

Wei Liu [http://orcid.org/0000-0002-9302-8170](http://orcid.org/0000-0002-9302-8170)

**References**

[1] Yu XI, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. 2011;364:1523–1532.

[2] Takahashi T, et al. The first identification and retrospective study of severe fever with thrombocytopenia syndrome in Japan. J Infect Dis. 2014;209:816–827.

[3] Kim KH, et al. Severe fever with thrombocytopenia syndrome, South Korea, 2012. Emerg Infect Dis. 2013;19:1892–1894.

[4] Liu MM, Lei XY, Yu XJ. Meta-analysis of the clinical and laboratory parameters of SFTS patients in China. Virol J. 2016;13:198.

[5] Li H, et al. Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China, 2011-17: a prospective observational study. Lancet Infect Dis. 2018;18:1127–1137.

[6] Zhan J, et al. Current status of severe fever with thrombocytopenia syndrome in China. Virol Sin. 2017;32:51–62.

[7] Yoo JR, et al. Mixed infection with severe fever with thrombocytopenia syndrome virus and two genotypes of *Scrub typhus* in a patient, South Korea, 2017. Am J Trop Med Hyg. 2018;99:287–290.

[8] Wang L, et al. Hemorrhagic fever with renal syndrome, Zibo city, China, 2006-2014. Emerg Infect Dis. 2016;22:274–276.

[9] Liu W, et al. *Candidatus rickettsia* tarasevichiae infection in eastern central China: a case series. Ann Intern Med. 2016;164:641–648.

[10] Lu QB, et al. Severe fever with thrombocytopenia syndrome complicated by co-infection with spotted fever group rickettsiae, China. Emerg Infect Dis. 2016;22:1957–1960.

[11] Tsioutis C, et al. Clinical and laboratory characteristics, epidemiology, and outcomes of *Murine typhus*: a systematic review. Acta Trop. 2017;166:16–24.

[12] Zhang Y, et al. Sero-epidemiological investigation on *Rickettsia typhi*, *Bartonella henselae* and *Orientia tsutsugamushi* in farmers from rural areas of Tianjin, 2007–2009. Zhonghua Liu Xing Bing Xue Za Zhi. 2011;32(3):256–259. (Chinese).

[13] Fu XP, et al. Surveillance on rickettsia in epidemic areas of *Scrub typhus* in Xinyang areas of Henan, Zhonghua Liu Xing Bing Xue Za Zhi. 2007;28 (6):547–549. (Chinese).

[14] Tsioutis C, et al. *Murine typhus* in elderly patients: a prospective study of 49 patients. Scand J Infect Dis. 2014;46(11):779–782.

[15] Chang K, et al. Characteristics of *Scrub typhus*, *Murine typhus*, and Q fever among elderly patients: prolonged prothrombin time as a predictor for severity. J Microbiol Immunol Infect. 2017;51(6):1137–1180.

[16] Moderzynski K, et al. CD4(+) T cells are as protective as CD8(+) T cells against *Rickettsia typhi* infection by activating macrophage bactericidal activity. Plos Neglect Trop Dis. 2016;10.

[17] Li XK, et al. Vascular endothelial injury in severe fever with thrombocytopenia syndrome caused by the novel bunyavirus. Virology. 2018;520:11–20.

[18] Liu W, et al. Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in China who had severe fever with thrombocytopenia syndrome. Clin Infect Dis. 2013;57:1292–1299.

[19] Regnery RL, Spruill CL, Plikaytis BD. Genotypic identification of rickettsiae and estimation of intraspecies sequence divergence for portions of two rickettsial genes. J Bacteriol. 1991;173:1576–1589.

[20] Jia N, Zheng YC, Jiang JF, et al. Human infection with *Candidatus rickettsia* tarasevichiae. New Engl J Med. 2013;369:1178–1180.

[21] Mediannikov OY, et al. Acute tick-borne rickettsiosis in a patient, South Korea, 2017. Am J Trop Med Hyg. 2018;99:287–290.

[22] Zhou X, et al. Co-infections with Babesia microti and *Plasmodium* parasites along the China-Myanmar border. J Clin Microbiol. 2004;42:90–98.

[23] Wen B, Jian R, Zhang Y, et al. Human infection with *Candidatus rickettsia* tarasevichiae. Ann Intern Med. 2016;164:641–648.

[24] Madani M, et al. Acute tick-borne rickettsiosis caused by *Rickettsia helongiangensis* in Russian Far East. Emerg Infect Dis. 2004;10:810–817.

[25] Labruna MB, et al. Rickettsia species infecting *Amblyomma cooperi* ticks from an area in the state of Sao Paulo, Brazil, where Brazilian spotted fever is endemic. J Clin Microbiol. 2004;42:90–98.

[26] Labruna MB, et al. Rickettsia species infecting Amblyomma cooperi ticks from an area in the state of Sao Paulo, Brazil, where Brazilian spotted fever is endemic. J Clin Microbiol. 2004;42:90–98.

[27] Medrano FE, et al. Simultaneous detection of *Anaplasma marginale* and a new *Ehrlichia* species closely related to *Ehrlichia chaffeensis* by sequence analyses of 16S ribosomal DNA in *Boophilus microplus* ticks from Tibet. J Clin Microbiol. 2002;40:3286–3290.

[28] Zhou X, et al. Co-infections with *Babesia microti* and *Plasmodium* parasites along the China-Myanmar border. Infect Dis Poverty. 2013;2:24.

[29] Bottsche E, Verbruggen E, Aubry C, et al. Meningoencephalitis complicating relapsing fever in traveler returning from Senegal. Emerg Infect Dis. 2012;18:697–698.
Appendix

Molecular test of SFTSV by real-time PCR

Viral RNA was isolated from serum samples using QIAamp Viral RNA Mini Kit (Qiagen), according to the manufacturer’s instructions. The real-time PCR was performed to detect SFTSV RNA with the use of the One step Primer Script RT-PCR Kit (TaKaRa) as previously described [18].

Molecular test of SFG rickettsia

DNA was isolated from blood specimens collected at admission with the use of the QIAamp Blood Mini Kit (Qiagen) according to manufacturer’s instructions. Nested PCR assays targeting the outer membrane protein A encoding gene (ompA), citrate synthase gene (gltA), and 17-kDa antigen-encoding gene were concurrently performed to detect the presence of SFG rickettsial DNA. Nucleotide sequences of the primers were shown in Appendix Table A1.

Molecular test of Anaplasmataceae

Nested PCR assays targeting the 16S rRNA gene (Eh16S rRNA) was concurrently performed to detect the presence of A. phygocytophilum DNA. Nucleotide sequences of the primers were shown in Appendix Table A1.

Molecular test of Babesia

Nested PCR assays targeting the SSU rRNA gene was concurrently performed to detect the presence of Babesia microti DNA. Nucleotide sequences of the primers were shown in Appendix Table A1.

Molecular test of B. burgdorferi sensu lato

The real-time PCR assays targeting the 16S rRNA gene (Bor16SrRNA) was concurrently performed to detect the presence of B. burgdorferi sensu lato DNA. Nucleotide sequences of the primers were shown in Appendix Table A1. Table A1. Nucleotide sequences of primers used in this study.

| Gene    | Primer Sequence (5′-3′) | Reference |
|---------|-------------------------|-----------|
| ompA    | R190.70p ATGGCAATATTTCTCCAAA [19] |
|         | R190.60z AGTGACGCGATCCGCTCCTCCCT [20] |
|         | 190.36-38s1 AAAAAACGCTTATACCC [21] |
|         | 190.60z-384r1 GGCAACAAGTTCCTCCTCTC [22] |
| gltA    | Cs1d ATGACATGCGATCATAAATAA [23] |
|         | CSEndr CTTATCCCTCCTGACAA [24] |
|         | Rps387p GGGAGCCTGTCGAGGGCGG [25] |
|         | Rps31238n ATGCCAAAGTACAGTGAAACA [26] |
| 17-kDa  | 17k-3 TGTCTACATATCGAGTTTGC [27] |
|         | 17kD1 GCTGCCGACAACCTTTGTTT [28] |
|         | 17kD2 CATTCTGTCGAGTTTGC [29] |
| Eh16S rRNA | Eh-out1 TTGAGATGCGTCTTTCCTG [30] |
|         | Eh-out2 CACCTTCATTGGAATTCCTG [31] |
|         | Eh-g1 GATACAGTTGACCTTCCTG [32] |
|         | Eh-g2 GAAGCTCATTATACCTCG [33] |

Table A2. Laboratory test results of the patients with R. typhi infection vs. SFTSV infection, 2014–2015.

| Laboratory parameters | R. typhi patients (n = 60) | SFTSV patients (n = 767) | P-value |
|-----------------------|---------------------------|--------------------------|----------|
| WBC count < 4 × 109/L | 49 (81.7) | 632 (82.4) | 0.886 |
| PLT count < 100 × 109/L | 41 (68.3) | 648 (84.5) | 0.001* |
| Neutrophils > 70% | 30 (50.0) | 350 (46.6) | 0.513 |
| Lymphocytes < 20% | 24 (40.0) | 278 (36.3) | 0.561 |
| HGB < 110 g/L | 9 (15.0) | 114 (14.9) | 0.977 |
| AST > 40 U/L | 44 (73.3) | 645 (84.1) | 0.031* |
| ALT > 40 U/L | 29 (48.3) | 438 (57.1) | 0.197 |
| ALB < 35 g/L | 5 (8.3) | 95 (12.4) | 0.354 |
| GGT > 50 U/L | 13 (21.7) | 174 (22.7) | 0.856 |
| LDH > 245 U/L | 48 (80.0) | 654 (85.3) | 0.273 |
| CK > 200 U/L | 32 (53.3) | 482 (62.8) | 0.144 |
| BUN > 7.14 mmol/L | 19 (31.7) | 247 (32.3) | 0.921 |
| CREA > 97 μmol/L | 6 (10.0) | 147 (19.2) | 0.077 |
| AMY > 115 U/L | 11 (19.9) | 183 (23.7) | 0.069 |
| Ca < 2.1 mmol/L | 24 (40.0) | 399 (54.9) | 0.115 |
| Cl < 95 mmol/L | 9 (15.5) | 89 (12.0) | 0.426 |
| K < 3.5 mmol/L | 32 (53.3) | 331 (43.2) | 0.128 |
| Na < 135 mmol/L | 44 (73.3) | 530 (69.2) | 0.502 |

Notes: All P values were 2-tailed and P < 0.05 was considered statistically significant. Categorical variables were analysed by chi-square test or Fisher’s exact test. WBC: White blood cell; PLT: Platelet count; HGB: Haemoglobin; AST: Aspartate aminotransferase; ALT: Alanine transaminase; ALP: Alkaline phosphatase; GGT: γ-glutamyl transpeptidase; LDH: Lactate dehydrogenase; CK: Creatine kinase; BUN: Blood urea nitrogen; CREA: Creatinine; AMY: Serum amylase; Ca: Calcium; Cl: Chlorine; K: Potassium; Na: Natrium.

Table A3. Demographic and clinical characteristics of the patient with fatal R. typhi infection.

| Characteristics | Age, years | Sex | Hospital duration | Delay days from onset to admission | Underlying diseases | Clinical manifestations | Common signs | Fever | Temperature | Malaise | Lymphadenectasis | Myalgia | Dizziness | Headache | Rash |
|-----------------|------------|-----|-------------------|-----------------------------------|---------------------|----------------------|---------------|-------|-------------|---------|----------------|--------|------------|----------|-------|
| Demographic characteristics | 64 | Male | 8 | 4 | Hypertension | | | + | 40 | - | + | - | - | - | - |
| Age, years | 64 | Male | 8 | 4 | Hypertension | | | + | 40 | - | + | - | - | - | - |
| Reported history of insect bite | - | | | | | | | | | | | | | | | |
| Hospital duration | 8 | | | | | | | | | | | | | | | |
| Delay days from onset to admission | 4 | | | | | | | | | | | | | | | |
| Underlying diseases | | | | | | | | | | | | | | | | |
| Clinical manifestations | | | | | | | | | | | | | | | | |
| Common signs | | | | | | | | | | | | | | | | |
| Fever | + | | | | | | | | | | | | | | | |
| Maximum temperature | | | | | | | | | | | | | | | | |
| Malaise | | | | | | | | | | | | | | | | |
| Lymphadenectasis | | | | | | | | | | | | | | | | |
| Myalgia | | | | | | | | | | | | | | | | |
| Dizziness | | | | | | | | | | | | | | | | |
| Headache | | | | | | | | | | | | | | | | |
| Rash | | | | | | | | | | | | | | | | |
| Anorexia | | | | | | | | | | | | | | | | |
| Respiratory syndrome | | | | | | | | | | | | | | | | |
| Cough | | | | | | | | | | | | | | | | |
| Productive cough | | | | | | | | | | | | | | | | |
| Gastrointestinal illness | | | | | | | | | | | | | | | | |
| Anorexia | | | | | | | | | | | | | | | | |

Continued.
Continued.

Table A4. Laboratory test results of the patient with fatal *R. typhi* infection.

| Laboratory parameters | Normal range | Patient |
|-----------------------|--------------|---------|
| WBC count (×10⁹/L)    | 4.0–10.0     | 5.0     |
| PLT count (×10⁹/L)    | 100–300      | 57      |
| Neutrophils (%)       | 50.0–70.0    | 83.6    |
| Lymphocytes (%)       | 20.0–40.0    | 14.0    |
| HGB (g/L)             | 110–170      | 136     |
| AST (U/L)             | 0–40         | 51      |
| ALT (U/L)             | 0–40         | 29      |
| ALB (g/L)             | 35.0–55.0    | 39.3    |
| ALP (U/L)             | 40–150       | 85      |
| GGTF (U/L)            | 7–50         | 15      |
| LDH (U/L)             | 109–245      | 313     |
| CK (U/L)              | 25–200       | 92      |
| BUN (mmol/L)          | 1.4–7.1      | 8.94    |
| CREA (μmol/L)         | 40–97        | 98      |
| AMY (U/L)             | 25–115       | 129     |
| Ca (mmol/L)           | 2.1–2.7      | 2.12    |
| Cl (mmol/L)           | 95–108       | 101     |
| K (mmol/L)            | 3.5–5.5      | 3.6     |
| Na (mmol/L)           | 135–155      | 131     |

Notes: WBC: White blood cell; PLT: Platelet count; HGB: Haemoglobin; AST: Aspartate aminotransferase; ALT: Alanine transaminase; ALB: Albumin; ALP: Alkaline phosphatase; GGT: γ-glutamyl transpeptadase; LDH: Lactate dehydrogenase; CK: Creatine kinase; BUN: Blood urea nitrogen; CREA: Creatinine; AMY: Serum amylase; Ca: Calcium; Cl: Chlorine; K: Potassium; Na: Natrium.